657409-24-0Relevant academic research and scientific papers
TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS
-
Page/Page column 58; 64, (2021/01/29)
The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
Multicyclic bis-amide MMP inhibitors
-
Page/Page column 91-92, (2008/06/13)
The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.
Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects
Suh, Young-Ger,Lee, Yong-Sil,Min, Kyung-Hoon,Park, Ok-Hui,Seung, Ho-Sun,Kim, Hee-Doo,Park, Hyoung-Geun,Choi, Ji-Yeon,Lee, Jeewoo,Kang, Sang-Wook,Oh, Uh-Taek,Koo, Jae-Yeon,Joo, Yung-Hyup,Kim, Sun-Young,Kim, Jin Kwan,Park, Young-Ho
, p. 4389 - 4393 (2007/10/03)
A novel non-vanilloid VR1 antagonist consisting of a new vanilloid equivalent exhibits excellent analgesic effects as well as highly potent antagonistic activities in both capsaicin single channel and calcium uptake assays. In addition, the structural requirement for the vanilloid equivalent of the potent VR1 antagonist has also been elucidated.
